April 01, 2025FinancialTerumo announces changes to the names of some businesses within the Cardiac and Vascular Company (PDF 117.21 KB) Disclosure segments of Blood and Cell Technologies Company to also be revised
April 01, 2025CorporateTerumo unveils "Our Promise," the long-term direction to be pursued by the entire groupThe company also launches a group brand video and visuals that express its unwavering commitment to improving patients’ lives
March 31, 2025CorporateTerumo opens new R&D center in the U.S. to strengthen global innovation capabilities
The Latest Materials 3rd Quarter Financial Results for FYE 3/2025 February 13, 2025 Financial Statements IFRS Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2025 (PDF 248.94 KB) Presentation Material Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2025 (PDF 543.7 KB) Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2025 (FY2024)(with note) (PDF 312.9 KB) Additional Information Revenue by Segment (PDF 291.85 KB) Revenue by Segment (Excel 228.14 KB) Q&A Q&A Session at the Financial Results Briefing for the Third Quarter of Fiscal Year Ending March 31, 2025 (PDF 237.28 KB) Webcast Listen to the Webcast Financial Statements /investors/library/financial-statements Presentations /investors/library/presentations Terumo Report /investors/library/annual-reports Sustainability /sustainability Corporate Governance /about/governance Consolidated Financial Statements /investors/library/financial Adobe Reader is required for viewing PDF files. Download Adobe Reader
IFRS Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2025 (PDF 248.94 KB)
Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2025 (FY2024)(with note) (PDF 312.9 KB)
Q&A Session at the Financial Results Briefing for the Third Quarter of Fiscal Year Ending March 31, 2025 (PDF 237.28 KB)